Study: RenalGuard Not Superior in Avoiding CIN in High-Risk Cases
A randomized controlled trial showed that RenalGuard is no better than conventional IV hydration at preventing contrast-induced nephropathy in high-risk patients.
Stay updated with breaking news from Study Evaluating. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A randomized controlled trial showed that RenalGuard is no better than conventional IV hydration at preventing contrast-induced nephropathy in high-risk patients.
Gluten can be a nightmare for people who have digestive problems or are gluten intolerant. Here are 2023 best gluten-free protein powders.
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from Phase 3 studies demonstrating patients treated with...
The FDA issued the final guidance document for first-in-human trial designs that consist of both dose escalation as well as multiple expansion...
Data also discussed in context of OVX836 clinical development update presentation at 2022 World Vaccine Congress Osivax, a biopharmaceutical company developing vaccines to protect against highly